• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
  • About Pompe
    • Diagnosing Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy

Maze Therapeutics Starting Phase I Clinical Trial with MZE001, A Substrate Reduction Therapy

by Victoria Radke | Feb 22, 2022 | News, Research & Studies

Recently, preclinical data were presented at the 18th Annual WORLDSymposium in San Diego, CA, supporting MZE001 as a treatment for Pompe disease.

Recent Posts

  • AVROBIO to Explore Strategic Alternatives
  • Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
  • International Pompe Day 2022
  • Julie
  • Brad
  • Terms
  • Privacy

Copyright © 2006 - 2023 Canadian Association of Pompe